

Invoice



Invoice							
Reference:	LE184752						
Order nr:	127035						
Date:	Mar 15, 2016						
Currency:	USD						
Product Information							
Quantity	Description	Unit price	VAT rate	VAT amount	Total amount (usd)	Paid (usd)	Due
1	Language editing	285.00	0.0%	0.00	285.00	285.00	0.00
					285.00	285.00	0.00
Customer Information							
Name:	Xiaolei Li						
Address 1:	Department of Molecular Biology,						
Address 2:	Institute of Basic Medicine,						
Postal code / zip:	100853						
City:	Beijing						
Country:	China						
Total VAT amount: USD 0.00							
VAT registration numbers: Austria (AT) U62029744, Belgium (BE) 454069965, Cyprus (CY) 99200008T, Czech Republic (CZ) 680459405, Denmark (DK) 17105779, Estonia (EE) 101100676, Finland (FI) 10123303, France (FR) 67390585230, Germany (DE) 172046177, Greece (GR) 999838602, Hungary (HU) 26952811, Ireland (IE) 9507113Q, Italy (IT) 00119309995, Luxembourg (LU) 21424724, Malta (MT) 18116507, Netherlands (NL) 801481247B01, Poland (PL) 5262786955, Portugal (PT) 980081963, Slovakia (SK) 4020110281, Slovenia (SI) 55336051, Spain (ES) A0063646D, Sweden (SE) 502048821801, Switzerland (CH) 494663, United Kingdom (GB) 494627212							

Paid in Full

MicroRNAs: novel immunotherapeutic targets in Colorectal Carcinoma

Abstract

Colorectal carcinoma (CRC) is one of the most common types of cancer ~~types~~ worldwide and the prognosis for CRC patients with recurrence or metastasis is extremely poor. Although chemotherapy and radiation therapy can improve survival, there are still numerous efforts to be ~~done~~performed. Immunotherapy is frequently used, either alone or in combination with other therapies, for the treatment of CRC and ~~exhibits is a safety~~ and ~~feasibility~~feasible way for to ~~improving~~ CRC treatment. Furthermore, the significance of the immune system in the biology of CRC has been demonstrated by retrospective assessments of immune infiltrates in resected CRC tumors. MiRNAs are short, non-coding RNAs that can regulate multiple target genes at the post-transcriptional level and play critical roles in cell proliferation, differentiation and apoptosis. MiRNAs are required for normal immune system development and function. Nevertheless, aberrant expression of miRNAs is often observed in various tumor types and leads to immune disorders or immune evasion. The immunomodulatory function of miRNAs indicates that miRNAs may ultimately be part of the portfolio of anti-cancer targets. Herein, we will review the potential roles of miRNAs ~~that in the~~ regulation of the immune response in CRC and then move on to ~~discussing~~ how to utilize different miRNA targets to treat CRC. We also provide an overview of the major limitations and challenges of using miRNAs as immunotherapeutic targets.

Key words: Colorectal Carcinoma (CRC), microRNAs (miRNAs), immunotherapy, tumor microenvironment, inflammation, IBD

Running title: miRNAs as immunotherapeutic tools.

Core tip

Colorectal carcinoma is one of the most common tumor types worldwide. Immunotherapy has been used to treat advanced CRC and has the potential to eradicate the disease by activating immune responses. MiRNAs play critical roles in regulating anti-tumor immune responses. There is a need to summarize the current

understanding of the diverse roles of miRNAs ~~involved~~ in ~~the regulating-regulation of~~ immune responses and ~~their~~ clinical applications for CRC immunotherapy.

Introduction

Colorectal carcinoma (CRC) is the third most common malignancy in males and the second in females, posing a serious demographic and economic burden worldwide. Although surgical resection for patients with localized disease has dramatically improved 5-year survival rates, more than half of all patients diagnosed with CRC eventually develop recurrence and metastasis. ~~In addition,~~ current strategies such as chemotherapy are approved for the treatment of CRC; however, these non-surgical therapeutics have only modest efficacy and are ineffective against distant metastases. Moreover, traditional strategies generate reverse events, such as cytotoxicity, that limit their use. Therefore, the prognosis of CRC patients remains poor and ~~presents~~ an opportunity to study future therapeutic approaches to improve clinical outcomes. Recently, immunotherapy has been used to treat advanced CRC and has the potential to eradicate ~~the disease~~ by activating immune responses. Some clinical trials utilizing immunotherapy have demonstrated objective responses in CRC patients. However, CRC is able to evade detection and elimination by the immune system, ~~resulting in and~~ the objective responses have been manifested in ~~only~~ a small fraction of patients with CRC. For example, the lack of CRC-associated antigens limits the development of immunotherapy. The important role of the immune system in the biology of CRC has been emphasized by retrospective assessments of immune infiltrates, affecting all aspects of CRC from tumorigenesis to treatment. Within the tumor microenvironment, immune infiltrates can act as suppressors of tumor initiation and progression, as well as promote the proliferation, infiltration and metastasis of CRC. The presence of tumor infiltrating lymphocytes (TILs), including CD8⁺ T cells, in the tumor microenvironment is ~~more~~ strongly associated with a better prognosis. Tregs suppress the proliferation and activation of CD4⁺ and CD8⁺ T cells and ~~the increase~~

~~of~~increased Tregs activation ~~are~~is correlated ~~in~~with poorer prognosis. The immune evasion of CRC has complex mechanisms. The induction of immune tolerance and resistance to ~~killing~~by activated immune effectors are two important mechanisms of CRC immune evasion. PD-1 is an inhibitory receptor that is overexpressed ~~in~~on nonfunctional and exhausted T cells in cancers. PD-1 and the ligands for PD-1 (PD-L1) have been implicated in escape from the immune system ~~by~~through directly suppressing antitumor CD8+ T cells. Furthermore, the recognition of tumor-associated antigens by immune effectors is one of the most important steps in antitumor immune responses. Thus, the dysregulation of antigens limits specific immune responses. For example, NY-ESO-1 ~~are~~is silenced in many tumor types. As a result, ~~s the~~ immune system cannot attack cancer cells through the recognition of the antigen. In all, the immune evasion is involved in the transformation of tumor cells and immune cells.

MicroRNAs (miRNAs) are approximately 19 to 25 nt in lengths ~~that~~and post-transcriptionally regulate gene expression in a sequence-specific manner by binding to the 3'-untranslated region (UTR), leading to either degradation of mRNA or a ~~blockading the~~ translation blockade. MiRNAs ~~have~~s emerged as crucial modulators in various biological processes such as proliferation, tumor initiation and development. Global dysexpression of miRNA has been identified in most types of tumors and has become a potential biomarker for tumor diagnosis, therapy and prognosis. MiRNAs were displayed to function as oncogenes or tumor suppressors according to their target mRNAs. For example, miR-484 is significantly decreased in microsatellite instability (MSI) CRC and functions as a tumor suppressor to inhibit MSI CRC cell viability. MiR-21 is upregulated in several tumors such as lung cancer, which ~~promotes~~ing tumor cell growth and metastasis. Recent studies have demonstrated that miRNA is coming to light as a ~~critical~~ regulators of immune responses and its aberrant expression or dysfunction in the immune system has been associated with cancers. MiRNA can either inhibit or enhance immune signals by regulating the expression of the positive or negative components of immune signaling pathways. MiR-181a expression appears to control T cell sensitivity to antigens

批注 [Ed1]: Please ensure the intended meaning has been maintained in this edit.

during T cell development and maturation. STAT3 has been shown to play an important role in tumor-mediated mechanisms of immunosuppression. MiR-124 was found to target the STAT3 signaling pathway and exerted potent therapeutic effects ~~through by~~ enhancing immune effector responses in cancer. Emerging evidence has demonstrated that immune-associated miRNAs ~~can cause~~ dysregulation in both tumor cells and immune cells, ~~that is, which suggests that~~ miRNA could be involved in communication between tumor cells ~~and to~~ immune cells ~~communication~~. MiR-124 is absent in all types of gliomas, and its upregulation in glioma cancer stem cells inhibits the ~~STAT3~~ pathway and reverses stem cells-mediated immune suppression of T cell proliferation and Treg activation. MiR-23a is upregulated in tumor-infiltrating cytotoxic T lymphocytes (CTLs) and impairs antitumor potential of patient CTLs by repressing the transcription factor BLIMP-1, which promotes CTL cytotoxicity and effector cell differentiation. However, the immunomodulatory roles of miRNAs in CRC still need to be further explored ~~in CRC~~. Therefore, in this review, we summarize the current understanding of the diverse roles of miRNAs involved in immune responses in CRC. We also discuss the clinical applications of miRNAs in CRC immunotherapy and the limitations and challenges in future use.

Regulation of immune-related miRNA biogenesis in CRC

The resulting primary miRNAs are processed into mature miRNAs through multiple biochemical steps. Our previous review and other excellent reviews have illustrated the mechanism of miRNAs biogenesis. Thus, we will not discuss it further here. In the ~~processes~~ of miRNA biogenesis, the RNase III endonuclease Dicer plays a critical role in the generation of miRNAs. Dicer has been reported to regulate miRNA biogenesis in regulatory T cells (Treg). Depleting miRNAs by silencing Dicer generates functional miRNAs, reduces Treg cell numbers and results in immune pathology. Previous studies have found that Dicer is required, in a cell-autonomous fashion, for the development of Tregs in the thymus. However, the mechanism by which the expression of Dicer in tumor cells ~~how to regulates~~ immune surveillance through miRNA processing ~~of miRNAs is needs~~ to be deeply explored. Indeed, Dicer depletion upregulates intercellular cell adhesion molecule 1 (ICAM-1) and enhances

批注 [Ed2]: Please ensure the intended meaning has been maintained in this edit.

the susceptibility of CRC cells to antigen-specific lysis by CTLs. ICAM-1 has an important role in physical and functional interaction between CRC cells and CTLs. Furthermore, Dicer-disrupted CRC cells downregulate the expression of miRNAs miR-222/339, which directly target ICAM-1 mRNA. Upregulation of ICAM-1 by repressing Dicer or miR-222/339 in CRC cells contributes to increased susceptibility of tumor cells to antigen-specific CTLs. Thus, Dicer is responsible for the generation of the mature miR-222/339, which represses the expression of ICAM ~~through-by~~ binding to the 3'UTR, thereby reducing the susceptibility of tumor cells to CTL-mediated cytotoxicity. These findings indicate ~~the viability of the~~ development of novel miRNA-targeted therapy to promote cytotoxicity of tumor cells in tumor immunotherapy.

MiRNAs regulate immune responses in the CRC tumor microenvironment

Immunotherapy-involved miRNAs in CRC cells

Multiple studies have been demonstrated that miRNAs play key roles in CRC tumor biology including; tumor initiation, progression, invasion and metastasis. Several miRNAs have been found to directly regulate the primary pathways of CRC initiation and development. The development of CRC follows the sequential progression from adenoma to malignant adenocarcinoma. Tumor protein 53 (TP53) is frequently ~~lost~~ during the progression of adenoma to adenocarcinoma. TP53 loss mediates apoptosis and cell cycle arrest through the inhibition of a direct downstream target, miR-34a. The upregulation of c-myc, the target of the miR-17-92 cluster, promotes the adenoma to adenocarcinoma transition. Uncontrolled growth and proliferation are key components in the development of colorectal tumorigenesis. The dysfunction of the PI3K pathway and its associated proteins play important roles in the cell cycle regulation of CRC. MiR-144 has been found to inhibit the PI3K pathway ~~through-by~~ negatively regulating mTOR. Upregulation of miR-195 promotes apoptosis ~~through-by~~ targeting BCL2 in CRC cells, whereas its inhibition enhances CRC cells survival. Emerging evidence has demonstrated that miRNAs are most frequently associated with the invasion and metastasis of CRC. Upregulation of miR-21 positively regulates invasion and metastasis ~~through-by~~ directly targeting

several tumor suppressor genes, including programmed cell death 4 (PDCD4), PTEN and CCL2 in CRC. MiRNAs could regulate CRC cell invasion and metastasis through the epithelial to mesenchymal transition (EMT). Activation of EMT allows CRC cells to migrate and metastasize to distant organs. Recent studies suggested that miRNAs are new EMT regulators and regulate CRC metastasis. Downregulation of the miR-200 family has been emerged-found to induce EMT through-by targeting ZEB1/2 in CRC cells, which resultsing in the development of CRC metastasis. Therefore, the dysregulation of miRNA is involved in the full range of CRC development.

According to previous reports, the immune system plays complex and multi-faceted roles in CRC, affecting all aspects of CRC initiation and metastasis. The body's immune system can act both as-to suppressors of tumor initiation and progression, as well as promote malignancies. During tumorigenesis, normal cells transform into neoplastic cells are-through multifactorial processes that including genetic and epigenetic factors, leading to the immune escape of tumor cells. Immune escape plays a key role for the success of tumor cells growth and survival through developing multiple suppressive mechanisms in the tumor microenvironment. More recently, miRNAs have been observed to play important regulatory roles in the immune system. The abnormal expression of co-inhibitory molecules of PD-L1 in the tumor microenvironment has been identified as an important immunosuppressive mechanism in many tumor types, and-that contributes to tumor immune escape through-by inhibiting T cell activation and proliferation. Furthermore, PD-L1 expression in CRC cells may be associated with the expansion of regulatory T cells (Tregs) in the tumor microenvironment, which suppresses the activation and proliferation of effector T cells, in-tumor-microenvironment. MiR-20b, -21 and -130b are upregulated in advanced CRC and inhibit PTEN expression resulting in PD-L1 overexpression. PTEN, a famous tumor suppressor gene, plays a critical role in CRC cell growth, proliferation and the occurrence of CRC. This study revealed a novel mechanism of PD-L1 protein expression mediated by miRNAs indirectly, which leads to the immune escape of CRC. Moreover, miR-34 has been found to modulate tumor escape through-by directly targeting PD-L1 in lung cancer. MiR-34a therapy elicits

tumor-infiltrating immune cells (CD8+ T cells) activation and decreases exhausted tumor-infiltrating immune cells (PD1/CD8+), indicating an active immune response and reduced tumor tolerance. These results suggest that the miRNA-PD-L1 axis may as-be a therapeutic targets for CRC immunotherapy and miRNAs may be implicated in checkpoint blockade therapy.

Cancer immunotherapy has the potential role to eliminate tumor cells by eliciting immune responses through the recognition of tumor-specific antigens on tumor cells. Numerous studies have reported that monoclonal antibody (mAb)-based immunotherapy against tumor antigens is a promising strategy and has been clinically effective as CRC therapeutics. Antibodies targeting tumor antigens block major pathways central to tumor cell proliferation and survival. Anti-human epidermal growth factor (anti-EGFR) antibodies, such as cetuximab and panitumumab, have been approved and routinely used for the treatment of CRC. EGFR, commonly overexpressed in CRC, leads to the stimulation of the oncogene KRAS that subsequently activates BRAF, which contributes to the promotion and progression of a broad spectrum of CRC. These two antibodies can trigger tumor antigen-specific cellular immunity to eliminate CRC cells. Recent studies have demonstrated that miRNAs could serve as predictive or prognostic biomarkers ~~to-for~~ anti-EGFR therapy in patients with wild-type KRAS (wt-KRAS) metastatic CRC (mCRC). Anti-tumor immune responses of antibody and EGFR signaling pathways have been shown to be regulated by miRNAs. MiRNAs miR-31-3p/5p have been confirmed as-to be strongly associated with time-dependent to-progression in wt-KRAS mCRC patients treated with cetuximab but not panitumumab, suggesting that miR-31-3p/5p should not be used as a predictor of response to panitumumab. Two reasons could explain the predictive role of miR-31-3p/5p for cetuximab: one associated with concomitant chemotherapy, and the second with different immune responses linked to cetuximab and panitumumab. Furthermore, the expression level of miR-31-3p is associated with progression-free survival, indicating that miR-31-3p seems to be a new mCRC biomarker ~~to-respond to-for~~ anti-EGFR therapy. Significant miR-31* upregulation and miR-592 downregulation show a markedly difference in progressive disease

批注 [Ed3]: Please ensure the intended meaning has been maintained in this edit.

~~compared with~~ in comparison to disease control. Moreover, the upregulation of some miRNAs, such as let-7 and miR-140-5p, ~~upregulation~~ as well as the downregulation of miR-1224-5p ~~downregulation~~ are significantly associated with poor overall survival, revealing that in mCRC patients with wt-KRAS/BRAF, miRNA profiling can efficiently predict the prognosis after anti-EGFR treatment. Interestingly, miRNAs can also directly or indirectly target EGFR signaling pathway and its signaling components. Therefore, miRNAs-EGFR signaling has been validated as a therapeutic target in CRC. EGFR has been found to control and negatively regulate the expression of miR-143 and miR-145 in CRC cell lines, two famous tumor suppressive miRNAs, which suggesting ~~suggests~~ that inhibition of EGFR may upregulate these two miRNAs expression and suppress tumor growth and progression. According to previous reports, wt-KRAS, a major factor ~~to that~~ drives CRC progression, is a necessary condition ~~of for~~ anti-EGFR treatment ~~indication~~ and it can be activated by the stimulation of EGFR. Several miRNAs, miR-143, miR-145, let-7 and miR-18a*, act as tumor suppressors and repress the expression of KRAS. In contrast ~~with to~~ targeting KRAS, KRAS can regulate the expression of miRNAs. Recent studies have demonstrated that KRAS upregulates the expression of some oncogenic miRNAs, including miR-200c, miR-221/222, miR-210 and miR-181a. These miRNAs act as oncogenic miRNAs and promote CRC progression. Therefore, the extensive involvement of miRNAs in regulating EGFR signaling pathway and its components ~~seems~~ suggests that miRNAs could ~~severe~~ serve as promising predictive biomarkers and therapeutic targets ~~to for~~ anti-EGFR therapy in CRC.

MiRNAs regulate stromal cells

Tumor tissues have two distinct regions: the tumor bed and TME. TME comprises fibroblasts, various immune cells and endothelial cells, along with extracellular matrix (ECM), proteases and cytokines. TME represents an integral part of tumors and establishes dynamic interactions with tumor cells that influence tumor growth, metastasis and immune tolerance. Stromal cells, including cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs) and mesenchymal stem cells (MSCs), are important components of TME and can shape anti-tumor

immunity and responsiveness to immunotherapy. MDSCs are a heterogeneous group of myeloid cells in early differential stages and one of the major elements of the immunosuppressive network responsible for effector T cell defective response in cancer. A pPrevious report has found that the number of blood MDSCs ~~numbers~~ correlates with the stage and metastatic in many tumor types, including CRC. MDSCs could inhibit the host immune response ~~into~~ tumor cells by interfering with immune cell responsiveness to interferon alpha and gamma in CT26 bearing mice. Although MDSCs contribute to immune invasion via ~~suppression of~~ CD4+ and CD8+ T cell anti-tumor functions, the molecular mechanisms involved in the expansion, function and infiltration of MDSCs are not fully understood. Numerous studies have demonstrated that miRNAs play key regulatory roles in MDSCs development, expansion and function. Recently, miR-17-5p and miR-20a have been found to alleviate the suppressive potential of MDSCs in the CT26 colon carcinoma model. The oOverexpression of miR-17-5p and miR-20a remarkably reduces the expression of reactive oxygen species (ROS) and the production of H₂O₂ by modulating the expression of STAT3. Furthermore, MDSCs transfected with miR-17-5p and miR-20a are less able to suppress antigen-specific CD4+ and CD8+ T cells. Thus, the modulation of miR-17-5p and miR-20a expression may play important roles for the process by which patients with a tumor can overcome the immune tolerance mediated by MDSCs and could potentially be applied ~~for-in~~ immunotherapy against CRC. MiR-494, whose expression was mainly upregulated by TGF-beta 1, has been identified as an essential player in the regulation of the accumulation and activity of MDSCs by targeting PTEN and ~~activation-activating the~~ PI3K/AKT pathway. Upregulation of miR-494 represses PTEN expression, resulting in increased activity of AKT pathway, and facilitates tumor cell invasion and metastasis by ~~upregulating on-of~~ MMPs in murine breast and colon cancers. These findings revealed that TGF-beta 1-induced miR-494 expression in MDSCs plays a critical role in regulating the accumulation and functions of MDSCs and may be identified as a potential target in cancer immunotherapy. Emerging studies have demonstrated that CD11b+Gr1+ MDSCs play an important role in the suppression of T cell responses

and the induction of T cell tolerance in tumors. Tumor-associated factors are related to an increased number of CD11b+Gr1+ MDSCs. MiR-223 and related miRNAs have been identified miRNAs related to myeloid development in myeloid expansion and differentiation. The expression of miR-223 was downregulated during the differentiation of CD11b+Gr+ MDSCs from bone marrow cells (BMCs) upon exposure to tumor-associated factors. Moreover, overexpression of miR-233 remarkably inhibits differentiation of BMCs into MDSCs by targeting myocyte enhancer factor 2c (MEF2C), which promotes the accumulation of MDSCs.

In addition to regulating stoma cells, miRNAs also play key roles in modulating the expression of cytokines or chemokines in TME. Chemokines, which are chemo attractant cytokines and are primarily known as critical regulators of the immune system, have been implicated in malignant transformation and tumor progression. In the TME, specific chemokines have been found to be responsible for the recruitment of leukocytes into tumor sites. In addition, chemokines also play an important role in the functionality of tumor cells and other cells in TME, which together modulate the processes of tumor development and progression. Emerging evidence has demonstrated that various miRNAs are shown to regulate different chemokines in the TME of CRC. Chemokine CCL20 was shown to regulate CRC progression and metastasis through binding to its receptor CCR6. Moreover, CCL20 and its receptor CCR6 are significantly increased in CRC. Interestingly, miR-21, a well-known oncomiR, has been identified to target CCL20 in CRC cells. Ectopic expression of miR-21 down-regulates CCL20 gene expression in different cell lines. These results seem to indicate that miR-21 may act as a tumor suppressor in this situation. However, for functional interaction of miR-21 with CCL20, both the two molecules must be present in the same cell. Furthermore, miR-21 and CCL20 are both significantly upregulated in CRC tissues. It's well-known that TME is composed of tumor cells and various types of stromal cells, such as fibroblasts and endothelial cells, as well various as immune cells. Thus, this suggests that miR-21 and CCL20 may not be expressed in the same cell in the TME of CRC. Actually, the vast majority of CCL20 expression found in CRC tissues is restricted to the mesenchymal cells, such as

批注 [Ed4]: Please ensure the intended meaning has been maintained in this edit.

macrophages and lymphocytes in the TME. Likewise, miR-21 expression is primarily detected in stromal cells, such as CAFs, and immune cells, such as macrophages, but not within tumor cells and lymphocytes in the TME of CRC tissues. These data clearly exclude the chance of miR-21 and CCL20 being expressed in the same cell of TME. It may also be speculated that CCL20 secreted by infiltrated-immune cells affects miR-21 expression in CAFs through the CCR6 signaling pathway. In our recent report, we found that methylation-induced loss of miR-484 in microsatellite-unstable (MSI) CRC promotes both cell viability and IL-8 (also known as CXCL8) production through-by targeting CD137L. CD137, a member of the TNF superfamily, can induce cell viability by triggering the activation of the PI3K and mTOR signaling pathways. Moreover, CD137L can signal back to tumor cells and induce the production of IL-8, which can promote tumor invasion by the recruitment of tumor-associated macrophages (TAMs) and neutrophils. However, CD137L expressed in CRC cells also functions as a co-stimulatory molecule for the production of IFN-gamma by human T cells. Thus, these results may indicate that miR-484 can play a suppressive role in anti-tumor immune responses in MSI CRC through repressing the expression of CD137L.

Inflammation-related miRNAs in CRC tumorigenesis

Unique miRNA profiles

Chronic inflammatory disorders are often associated with an increased risk of CRC tumorigenesis. CRC is preceded by clinically detectable inflammatory bowel disease (IBD), such as Crohn's disease (CD) and Ulcerative colitis (UC). Because of chronic damage to the colon and rectum in IBD, these patients are at increased risk for CRC. Increasing evidence has demonstrated that miRNA dysregulation is an important pattern in IBD. Elevated miR-150 was found in UC and reduced the expression of c-myc, a transcription factor known to regulate the anti-apoptotic protein, BCL-2. Several studies have found that increased cytokines, such as TNF, IL and interferon, caused apoptosis and play an important role in the-intestinal epithelial cells. Apoptosis can interrupt intestinal mucosal integrity and barrier function and eventually resulting in inflammation. MiR-29a has been found to promote intestinal

epithelial apoptosis in UC by directly targeting myeloid cell leukemia 1 (Mcl-1), which is an anti-apoptotic BCL-2 family member and essential for the survival of multiple cell lineages. Moreover, five miRNAs expressions were increased and two expressions were decreased in CD ~~compared-in comparison~~ to healthy controls. Although both CD and UC are ~~the~~-subtypes of IBD, the expression patterns of miRNAs show region-specific differences and are expressed differentially. Eight different miRNAs could be used to distinguish active CD ~~from~~ active UC. The expressions of miR-23b/106/191 ~~were~~ increased in active UC tissues, while miR-19b/629 were decreased in Crohn's colitis patients. Given these common changes in miRNA expression profiles in IBD, ~~thus~~-these miRNAs may be involved in regulating central components of the immune system.

MiRNAs regulate inflammatory pathways

Numerous studies have demonstrated that miRNAs can regulate many inflammation-associated pathways in IBD. ~~The~~ IL-6-STAT3 signaling pathway plays an important role in IBD, and specifically STAT3 is up-regulated in UC. This pathway regulates the development of UC and has been implicated in the progression of UC to CRC. Recently, miRNAs have been identified ~~to-be~~ as a potent regulator of STAT3 activity in human colonocytes. MiR-124 is down-regulated in children with active UC, resulting in increased levels of STAT3 expression and the transcriptional activation of its downstream targets, which could promote inflammation and ~~the~~ pathogenesis of UC in children. The vitamin D receptor (VDR) is highly expressed in the epithelial cells of ~~the~~ gut mucosal epithelial barrier and plays a critical role in maintaining the integrity of the mucosal epithelial barrier by suppressing inflammation-induced intestinal epithelial cells apoptosis. Epithelial VDR levels are reduced by more than 50% in IBD and promote colitis. MiRNAs have been identified to be involved in the downregulation of VDR. Pro-inflammatory cytokine TNF-alpha suppresses epithelial VDR expression through induction of miR-346. TNF-alpha is one of the most important cytokines in regulating the development of colitis, and anti-TNF therapy is a standard therapy in the management of IBD. Thus, ~~use of~~ TNF-alpha as an inflammatory mediator to inhibit VDR ~~will-makes good~~-sense. Further, TNF-alpha is

markedly increased and may serve as an objective index of inflammatory activity in human UC. ~~A r~~Recent report has found that miR-19a, which ~~is~~ downregulated in UC, directly targets the expression of TNF-alpha, ~~thus and~~ induces the expression of downstream inflammation targets IL-8 and GM-CSF. Immune dysregulation is thought to play ~~a~~ critical roles in the pathogenesis of CD. Cytokines are involved in immune regulation and ~~the~~ dysregulation of cytokines contributes to heightened inflammation. Therefore, cytokine signaling ~~pathways~~ may be useful targets for CD. MiRNA miR-19b has been reported to regulate cytokine signaling ~~through by~~ directly targeting suppressors of cytokine signaling (SOCS). SOCS proteins are important physiological regulators of immune responses and negatively regulate cytokines expression through ~~the~~ JAK/STAT pathway. ~~Thus, this study will provide potential evidence for the development of miR-19b-based anti-inflammation therapies for CD treatment.~~ Neurotensin (NT) is a neuropeptide expressed in the central nervous system and the intestines, while NT receptor 1 (NTR1), the high-affinity receptor of NT, is expressed in neurones and colonic epithelial cells. In the colon, ~~the~~ NT/NTR1 signaling pathway can promote inflammation in acute colitis and their expression increases in ~~the~~ patients with UC. NT induces miR-133a expression in colonic epithelial cells. Moreover, miR-133a modulates NT-induced MAP kinase and NF-kappa B activation, as well as transcription of pro-inflammatory cytokines, such as IL-6/8/1beta, ~~through by~~ inhibiting aftiphilin (AFTPH) expression. This study may represent a promising strategy to ~~inhibiting~~ miR-133a and ~~restoring-restore~~ AFTPH expression for the treatment of IBD.

MiRNAs regulate immune responses

Immune responses play important roles in connecting inflammation and CRC. IBD has been connected to predisposing genetic factors ~~that~~ ~~contribut~~eing to abnormal immune responses. For example, adaptive immune system involved genes that have been linked to IBD include components of the IL-23 signaling pathway, which ~~are~~is required for induction of Th17 cells. Interestingly, ~~a~~ recent study has found that the intracellular sensor NOD2 can induce miR-29 expression in human dendritic cells (DCs) to limit IL-23 release. NOD2 is required for the induction of

批注 [Ed5]: Please ensure the intended meaning has been maintained in this edit.

miR-29; ~~and~~ miR-29 downregulates IL-23 and attenuates Th17 cells responses in CD. Activation of NOD2 has a key role ~~into~~ ~~influcinge~~ the release of pro-/anti-inflammatory cytokines, particularly IL-1beta/6/8/23. Furthermore, activation of NOD2-dependent pathways contributes to the induction of NF-kappa B, as well as the activation of JNK and p38 MAPK. NOD2 not only induces miRNA expression but also has been identified as a functional downstream target of several miRNAs. MiR-122 and miR-192 can directly target NOD2 and suppress the expression of NOD2. Ectopic expressions of these two miRNAs ~~respectively~~ inhibit NOD2 expression, NF-kappa B activation and immune responses, ~~respectively~~. Furthermore, miRNAs ~~are~~ ~~also~~ ~~as~~ pivotal regulators of Th17 cells differentiation and function. MiR-210 has a particularly important role in regulating Th17 cell lineage, ~~as well as~~ ~~is~~ ~~and~~ ~~is~~ a signature miRNA of hypoxia. The expression of miR-210 ~~increases~~ ~~is~~ rapidly ~~increased~~ in hypoxia-challenged Th17 cells. Hypoxic conditions inhibit ~~degradation of~~ the subunits of HIF-1, HIF-1alpha ~~degradation~~ and lead to ~~its~~ ~~their~~ stabilization. ~~And~~ HIF-1 plays important roles in regulating Th17 differentiation. Intriguingly, miR-210 directly targets HIF-1alpha and reduces HIF-1alpha transcript abundance and the proportion of cells ~~producing that produce~~ inflammatory cytokines, and controls IND severity. In addition to regulating Th cells differentiation, miRNAs can regulate leukocyte migration ~~through by~~ targeting chemokines. MiR-141 regulates colonic leukocyte trafficking via directly targeting CXCL12 beta during intestinal inflammation of CD. The miR-141-CXCL12 beta pathway contributes significantly to the development of CD, likely by affecting the recruitment of immune cells into the inflamed colonic tissue. Therefore, repressing colonic CXCL12 beta and immune cell recruitment with miRNA represents a feasible and promising strategy that may be valuable for the treatment of CD. Moreover, the expression of a number of intestinal epithelial cell-derived chemokine was regulated by miRNAs. MiR-192 was dramatically upregat~~edion~~ in UC and regulated the expression of macrophage inflammatory peptide-2 (MIP-2alpha), which is a chemotactic chemokine secreted by colonic epithelial cells and macrophages. Recently, miRNAs have been found to regulate gut mucosal immunity via epithelium-T-cell crosstalk. MiR-375 regulates gut

mucosal immunity ~~through-by~~ modulating the differentiation of goblet cells ~~and-~~ targeting the expression of TSLP and RELM-beta, a Th-2-facilitating epithelial cytokine and an important goblet cell effector, respectively.

Perspectives and challenges

The limitations of surgery and chemo/radio therapies to treat CRC patients necessitate the development of novel strategies, including immunotherapy. Tremendous progress has been made in understanding the role of the immune system in driving the development of CRC. Immune cells markers could be used to predict CRC outcomes, while targeting various aspects of the immune system could be used to generate anti-tumor immune responses. Unfortunately, effective ~~immunotherapies~~ immunotherapy in CRC treatment remains elusive. The ultimate goal of immunotherapy is to recruit the immune effectors to ~~destroy~~ cancer cells. However, immune escape leads to the failure of immunotherapy. ~~It has been proposed that cancer cells use~~ immune escape ~~is the proposed ability of the cancer cells~~ to evade the recognition and killing of the host immune system. For example, the expression of B7, a co-stimulatory molecule, has been found to be involved in CRC progression and immune surveillance escape mechanism. Furthermore, STAT3 regulates key pathways ~~that~~ mediating immune escape in the tumor microenvironment. Therefore, novel approaches need to be identified to overcome immune escape. Although several trials utilizing cancer vaccines or immune-checkpoint therapies have demonstrated objective responses in immunized patients with mCRC, more work is needed.

MiRNAs are deregulated and play critical roles in CRC. Initially, miRNAs have been found to act as oncogenic or tumor suppressor genes and regulate tumorigenesis, angiogenesis, progression, invasion and metastasis. The discoveries of miRNAs have opened a new era of CRC research and ~~the~~ potential of novel therapies for CRC treatment. Recently, miRNAs have been identified to regulate immune responses in CRC. The fact that miRNAs regulate tumor behaviors through targeting multiple genes, including immune associated genes, makes them excellent candidates for gene therapy. Therefore, ~~the ability to use miRNA-based therapy~~ ~~how~~ to restore a

dysfunctional immune system ~~by miRNA-based therapy~~ to a healthy state needs to be deeply studied. Generally, restoring the expression of tumor suppressor miRNAs or inhibiting the expression of oncogenic miRNAs has been employed for the development of miRNA-based therapeutics. In this regard, an example such as inducing ~~the~~ miR-34a expression has been found to elicit tumor-infiltrating CD8+ T cells activation ~~bythrough~~ targeting PD-L1. Therefore, the miRNA-target mRNA axis may be another novel immunotherapeutic target for CRC treatment. For example, STAT3 has been identified to play a pivotal role in a wide variety of tumor-mediated immunosuppression and is one of the first candidates that researchers assessed for potential miRNA binding. MiR-124 can enhance immune effectors responses by directly inhibiting the activation of the STAT3 signaling pathway. Because aberrant activation of STAT3 pathway ~~is occurred~~occurs in each stage of CRC tumorigenesis, including inflammation, adenoma and carcinogenesis, ~~thus~~ targeting diverse miRNA-STAT3 axis in specific pathological stages may ~~have better~~improve therapeutic efficacy. In addition, combinational therapies are ~~the~~ promising approaches for CRC immunotherapy. As ~~is known in the~~shown above, PD-L1 is the target of miR-124. MiR-124 therapy and PD-L1 monoclonal antibody therapy combinations will elicit stronger anti-tumor immune responses. Furthermore, miRNAs are known to target networks of genes and this may provide a unique therapeutic advantage. Therefore, altering the expression of multiple miRNAs ~~expression~~ simultaneously ~~by through~~ repressing distinct targets is a potential approach for CRC treatment.

MiRNAs exhibit ~~diverse~~ly immunomodulatory effects through their action on multiple mRNA species, ~~because~~ because they control many important immunological processes. Although ~~the~~ great efforts ~~that~~ have been ~~committed~~ made to discover the precise role of miRNAs in ~~regulating~~ anti-tumor immune response regulations, there are many challenges for the development of miRNA-based immunotherapy. These challenges include screening tissue-specific profiles, target identification, safe delivery to specific tissue, off-targets and biological safety. According to previous reports, miRNA expression is deregulated in tumor tissues compared ~~with to~~ normal

tissues and each patient has specific miRNA profiles. Thus, ~~how~~ the ability to identify ~~some~~ distinct miRNAs to treat CRC needs to be deeply explored. Moreover, although many computational algorithms have been developed to identify potential targets, many critical functional miRNA targets ~~couldn't~~ could not be identified due to the inability of bio-~~informatic~~ informatics predictions to find miRNA binding sites with seed mismatches. Fortunately, novel approaches have been developed to overcome these limitations. The major challenge in miRNA-based immunotherapy is the safe delivery to specific tissues without side effects. Moreover, there are challenges ~~that~~ how to ensure that miRNAs reach the tumor microenvironment rather than other organs. To overcome these delivery and biological safety hurdles, some effective and marketable strategies, such as viral and non-viral strategies, have been developed. However, ~~these~~ novel approaches are needed to determine the efficacy of immune responses in clinical applications. In addition, another obstacle faced is ~~that~~ whether exogenous miRNAs can precisely regulate their target targets in tumor cells. Therefore, there is a long way to go before we resolve many technical and biological challenges. Nevertheless, the successful ~~of~~ development of miRNA-based immunotherapy has attracted the attention of many researchers.